TY - JOUR
AU - Jermano, John
AB - Abstract Background: We conducted a trial to compare treatment with zidovudine or didanosine in patients with advanced human immunodeficiency virus type 1 (HIV-1) infection who had received little or no previous therapy with zidovudine. Methods: Six hundred seventeen patients with acquired immunodeficiency syndrome (AIDS), advanced AIDS-related complex (CD4 cell count, ≤0.30× 109/L [300/μL]), or asymptomatic HIV (CD4 cell count, ≤0.20× 109/L) received zidovudine, 500 mg/d of didanosine, or 750 mg/d of didanosine in a randomized, double-blind allocation, with cross-over to alternative medication after development of an end point or serious toxic effect. To be eligible, patients must have received either no or up to 16 weeks of zidovudine therapy before entry into the study. Primary end points were development of a new AIDS-defining event or death. Secondary clinical end points were new or recurrent AIDS-defining events, or death, and survival. Results: In the study as a whole, there were no differences in the relative risks (RRs) of the development of end points between treatment groups. However, there was a strong interaction between the relative efficacies of zidovudine and didanosine and previous experience with zidovudine. Among 380 patients with no previous zidovudine therapy, zidovudine was more effective than 750 mg/d of didanosine (RR, 1.43; 90% confidence interval [CI], 1.02 to 2.00), with a similar trend for zidovudine compared with 500 mg/d of didanosine (RR, 1.21; 90% CI, 0.86 to 1.71). However, among 118 patients with more than 8 weeks but no more than 16 weeks of previous zidovudine therapy, 500 mg/d of didanosine was more effective than zidovudine (RR, 0.48; 90% CI, 0.27 to 0.86); there was a similar trend for increased effectiveness of 750 mg/d of didanosine compared with zidovudine (RR, 0.61; 90% CI, 0.36 to 1.03). Among 119 patients who had some but no more than 8 weeks of previous zidovudine therapy, there were no significant differences among the treatment arms. Similar findings were noted in the analysis of the two secondary clinical end points. No significant differences were found in efficacy between the groups receiving 500 and 750 mg/d of didanosine. The major toxic effect associated with zidovudine was hematopoietic (granulocytopenia) and that associated with didanosine was pancreatitis (dosage, 750 mg/d). Conclusions: In patients with advanced HIV disease, zidovudine appears to be more effective than didanosine as initial therapy; however, some patients with advanced HIV disease may benefit from a change to didanosine therapy after as little as 8 to 16 weeks of therapy with zidovudine.(Arch Intern Med. 1995;155:961-974) References 1. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/ LAV) by 2′,3′-dideoxynucleosides. Proc Natl Acad Sci USA . 1986;83:1911-1915.Crossref 2. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med . 1987;317:185-191.Crossref 3. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial. Ann Intern Med . 1990;112:727-737.Crossref 4. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection: results of the Veterans Affairs Cooperative Study. N Engl J Med . 1992;326:437-443.Crossref 5. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4 positive cells per cubic millimeter. N Engl J Med . 1990;322:941-949.Crossref 6. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science . 1989;243:1731-1734.Crossref 7. Rooke R, Tremblay M, Soudeyns H, et al. Isolation of drug resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS . 1989;3:411-415.Crossref 8. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr . 1990;3:743-746. 9. Yarchoan R, Mitsuya H, Thomas RV, et al. In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science . 1989;245:412-415.Crossref 10. Cooley TP, Kunches IM, Saunders CA, et al. Once-daily administration of 2′,3′-dideoxyinosine (didanosine) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: results of a phase I trial. N Engl J Med . 1990;322:1340-1345.Crossref 11. Lambert JS, Seidlin M, Reichman RC, et al. 2′,-3′-dideoxyinosine (didanosine) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: a phase I trial. N Engl J Med . 1990;322:1333-1340.Crossref 12. Yarchoan R, Pluda JM, Thomas RV, et al. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet . 1990;336:526-529.Crossref 13. Kahn JO, Lagakos SW, Richman DD, Cross A, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med . 1992;327:581-587.Crossref 14. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med . 1987;317:192-197.Crossref 15. Connolly KJ, Allan JD, Fitch H, et al. Phase I study of 2′-3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. Am J Med . 1990;91:471-478.Crossref 16. Kahn J. New developments in the clinical use of didanosine. J Acquir Immune Defic Syndr . 1993;6( (suppl 1) ):647-650. 17. Schacter LP, Rozencweig M, Beltangady M, et al. Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease. Blood . 1992:80:2969-2976. 18. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis . 1974;27:365-375.Crossref 19. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep . 1987;36( (suppl) ):3S-15S. 20. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis . 1988;158:1079-1083.Crossref 21. Knupp CA, Stancato FA, Papp EA, Barbahiya RH. Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography. J Chromatogr . 1990;533:282-290.Crossref 22. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. JAm Stat Assoc . 1958;53:457-481.Crossref 23. Cox DR. Regression models and life tables. J R Stat Soc B . 1972;34:187-220. 24. Spruance SL, Pavia AT, Peterson D, Berry A, et al. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. Ann Intern Med . 1994;120:360-368.Crossref 25. Seidlin M, Lambert JS, Dolin R, Valentine FT. Pancreatitis and pancreatic dysfunction in patients taking dideoxyinosine. AIDS . 1992;6:831-835.Crossref 26. Tersmette M, Lange J, deGoede R, et al. Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet . 1989;1:983-985.Crossref 27. Koot M, Vos AHV, Keet RPM, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS . 1992; 6:49-54.Crossref 28. Richman DD, Guatelli, JC, Grimes J, Tsiatis A, Gingeras T. Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction. J Infect Dis . 1991;164:1075-1081.Crossref 29. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis . 1993;167: 526-532.Crossref 30. Schnittman SM, Greenhouse JJ, Psallidopoulos MC, et al. Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med . 1990;113:438-443.Crossref
TI - Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine
JF - Archives of Internal Medicine
DO - 10.1001/archinte.1995.00430090111012
DA - 1995-05-08
UR - https://www.deepdyve.com/lp/american-medical-association/zidovudine-compared-with-didanosine-in-patients-with-advanced-hiv-type-1PCH3nUntq
SP - 961
EP - 974
VL - 155
IS - 9
DP - DeepDyve
ER -